- Home
- NXTC
NXTC
NextCure Inc.
as 11-10-2025 12:37pm EST
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BELTSVILLE |
| Market Cap: | 24.6M | IPO Year: | 2019 |
| Target Price: | $23.00 | AVG Volume (30 days): | 85.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.69 - $19.20 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NextCure Inc. News
NXTC Breaking Stock News: Dive into NXTC Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
Simply Wall St.
24 days ago
Companies Like NextCure (NASDAQ:NXTC) Could Be Quite Risky
GlobeNewswire
a month ago
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
Pharmaceutical Technology
5 months ago
NextCure and Simcere partner to develop SIM0505 for solid tumours
GlobeNewswire
5 months ago
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
Insider Monkey
5 months ago
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
GlobeNewswire
5 months ago
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
GlobeNewswire
6 months ago
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
Compare NXTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NXTC NextCure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.